Which drugs should we be testing for bioavailability [editorial]?

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|2|1|5-7

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.2, Iss.1, 1975-02, pp. : 5-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Which systematic review should we follow?

By Zou Kun   Zhang Weiya  

British Journal of Rheumatology , Vol. 52, Iss. 5, 2013-05 ,pp. : 763-764

Oxford University Press

Access to resources Recommend Favorite

C‐peptide: should we be testing this routinely in the Type 1 diabetes clinic?

By  

DIABETIC MEDICINE, Vol. 742-3071, Iss. 10, 2015-10 ,pp. : 1259-1260

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluating Fine Motor Coordination in Children Who Are Not Ready for Handwriting: Which Test Should We Take?

By  

OCCUPATIONAL THERAPY INTERNATIONAL, Vol. 22, Iss. 2, 2015-06 ,pp. : 61-70

John Wiley & Sons Inc

Access to resources Recommend Favorite

Which Comorbid Conditions Should We Be Analyzing as Risk Factors for Healthcare-Associated Infections?

By  

Infection Control & Hospital Epidemiology, Vol. 38, Iss. 4, 2016-12 ,pp. : 449-454

Cambridge University Press

Access to resources Recommend Favorite

Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen

By Garattini Livio  

The European Journal of Health Economics, Vol. 8, Iss. 2, 2007-06 ,pp. : 171-171

Springer Publishing Company

Access to resources Recommend Favorite